egy of the companies was used to pro-mote and market the products. No stud-ies have used internal documents to characterize the role of authorship in collaborations between industry and the medical profession. Inc related to rofecoxib provided a unique opportunity to examine the practice of guest authorship and ghost-writing related to the research and pro-motion of this medication. Our objec-tive was to provide a review using a case-study exploration of court docu-ments, in tandem with a review of the medical literature, to describe the prac-tice of guest authorship and ghostwrit-ing related to rofecoxib. Documents used for this article are posted at http://dida.library.ucsf.edu. METHODS In the course of the combined trials of Cona vs Merck and Co, Inc (No. ATL-L-3553-05, New Jersey Superior Court, Atlantic City) and McDarby vs Merck and Co, Inc (No. ATL-L-1296-05, New Jersey Superior Court, Atlantic City), millions of documents were made avail-able to and archived in an integrated da-tabase maintained by the plaintiff’s at-torneys. These documents were created between 1996 and 2004 and included Merck internal and external correspon-dence, reports, and presentations. As consultants to attorneys on the behalf of plaintiffs, we had complete access to all archived documents. One investi-gator (J.S.R.) searched the database to extract a subset of documents related
This is the end of the preview.
access the rest of the document.